Latest AstraZeneca Stories

Actavis Confirms Appeals Court Issues Injunction Related to Generic Pulmicort RESPULES® Distribution

2013-05-24 16:23:16

PARSIPPANY, N.J., May 24, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that the United States Court of Appeals for the Federal Circuit has granted a motion by AstraZeneca to enjoin Actavis from further distribution of its generic version of AstraZeneca's Pulmicort RESPULES(®) (budesonide inhalation suspension) 0.25, 0.5 mg products, pending resolution of AstraZeneca's appeal before the Court. Actavis launched its generic product on April 1, 2013, following a...

Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines

2013-05-24 04:20:39

BEIJING, May 24, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that Sinovac Beijing, the main operating subsidiary company of Sinovac, obtained the Certificate of Good Manufacturing Practices for Pharmaceutical Products (GMP Certificate) from the China State and Food Administration (CFDA) for its proprietary vaccines, its Haidian district bulk production plants, and its Changping filing and packaging...

Dr. Heiri Gugger named Managing Director of new North Carolina office

2013-05-22 08:30:24

RESEARCH TRIANGLE PARK, N.C., May 22, 2013 /PRNewswire/ -- Kincannon & Reed, the leading global retained executive search firm serving the agribusiness, food, and life sciences sectors, has named Dr. Heiri Gugger as Managing Director of the firm's new office in Research Triangle Park, NC. The firm will support North Carolina's fast-growing agribusiness and biotechnology sectors by recruiting the top talent needed to lead these businesses forward both locally and globally. Dr....

Par Pharmaceutical Begins Shipment of Generic Atacand®

2013-05-22 08:29:35

WOODCLIFF LAKE, N.J., May 22, 2013 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has entered into an exclusive U.S. supply and distribution agreement with AstraZeneca to distribute the authorized generic version of AstraZeneca's Atacand(®) (candesartan cilexetil). Par has begun shipping 4 mg, 8 mg, 16 mg and 32 mg strengths of candesartan cilexetil tablets. According to IMS Health data, annual U.S. sales of Atacand(®) are approximately $113 million....

Syngenta Opens Unique $72 Million Advanced Crop Lab

2013-05-17 23:03:57

Syngenta unveiled its new crop research facility during a grand opening celebration today at the company’s RTP Innovation Center. The first of its kind, $72 million Advanced Crop Lab allows company researchers to simulate any agricultural climate and precisely measure plant inputs – the key to helping farmers grow more food from fewer resources. RESEARCH TRIANGLE PARK, N.C., USA (PRWEB) May 17, 2013 • First of its kind research facility...

Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results

2013-05-17 04:20:46

BEIJING, May 17, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its unaudited financial results for the first quarter ended March 31, 2013, before market on Tuesday, May 28, 2013. The Company will host a conference call on Tuesday, May 28, 2013, at 8:00 a.m. EDT (May 28, 2013 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate...

A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing

2013-05-17 00:20:09

The vaccine based on Cytos' Virus-Like Particle technology may open the door to accelerated production of influenza vaccines in SingaporeSingapore and Schlieren (Zurich), Switzerland, May 17, 2013 - (ACN Newswire) - Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their H1N1 influenza vaccine candidate based on Cytos'...

Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting

2013-05-15 08:30:29

BOULDER, Colo., May 15, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced presentations on its MEK inhibitors, MEK162 (licensed to Novartis) and selumetinib (licensed to AstraZeneca) at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 - June 4, 2013 in Chicago, Illinois. Both MEK inhibitors are expected to advance into Phase 3 trials in 2013: Novartis expects to evaluate MEK162 in NRAS- and BRAF-mutant melanoma...

Sinovac Appoints Ernst & Young Hua Ming Llp China as External Auditor

2013-05-15 08:29:21

BEIJING, May 15, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, has appointed China-based Ernst & Young Hua Ming LLP as its registered independent public accounting firm effective from May 14, 2013 to replace Ernst & Young LLP Canada. On May 14, 2013, Ernst & Young LLP Canada notified the Company that it would not stand for re-election as the Company's registered independent public accounting firm....

Sinovac Presents at the UBS Global Healthcare Conference in May 2013

2013-05-14 08:31:46

BEIJING, May 14, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that management is scheduled to present at the UBS Global Healthcare Conference in New York City. The Sinovac management team inclusive of Nan Wang, Vice President, and Helen Yang, Director, Investor Relations and International Business Development, will present at 10:00 am ET on Monday, May 20, 2013. About Sinovac Sinovac...